IGC Pharma Announces Equity Research Update by Alliance Global Partners
Rhea-AI Summary
IGC Pharma (NYSE American: IGC) announced that Alliance Global Partners published an updated equity research report on February 10, 2026. The report reiterates a Buy rating and sets a $3.00 price target per share. IGC disclaims endorsement and does not guarantee the report's accuracy.
Positive
- Alliance Global Partners reiterated a Buy rating on IGC
- Analyst price target $3.00 per share (dated February 10, 2026)
Negative
- IGC explicitly does not endorse or guarantee the analyst report's accuracy
News Market Reaction – IGC
In the Feb 10 session, IGC gained 3.79%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Clinical trial update | Positive | +1.5% | Reached ~70% enrollment in Phase 2 CALMA trial for Alzheimer’s agitation. |
| Jan 22 | Clinical site addition | Positive | +7.3% | New Brooklyn clinical site added to CALMA Phase 2 to support enrollment. |
| Jan 12 | Clinical site expansion | Positive | -0.1% | Lightship network site added using hybrid model to broaden trial access. |
| Jan 06 | Corporate reporting change | Positive | -1.3% | Fiscal year-end shifted to Dec 31 to improve U.S. reporting comparability. |
| Jan 05 | Capital raise | Negative | +0.6% | Registered direct offering at $0.30 to fund IGC-AD1 Phase 2 development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent IGC news shows more divergences than alignments: positive clinical and corporate updates sometimes saw flat or negative moves, while a dilutive capital raise saw a small gain.
Over the past months, IGC has focused on advancing its Phase 2 CALMA trial of IGC-AD1, adding new sites in New York and Virginia and reaching about 70% enrollment by Feb 2, 2026. The company also raised capital through a registered direct offering of 779,997 shares at $0.30 and aligned its fiscal year with the calendar year. Against this backdrop of trial progress, financing, and reporting changes, today’s analyst research update fits into a narrative of ongoing execution rather than a new clinical or regulatory catalyst.
Key Terms
equity research financial
price target financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
POTOMAC, MARYLAND / ACCESS Newswire / February 10, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Alliance Global Partners ("AGP") has published an updated equity research report covering the Company.
The report reiterates a Buy rating and includes a price target of
A copy of the report may be obtained from AGP: Link.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information:
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire